The Efficacy, Tolerability and Joint Safety of Fasinumab in Osteoarthritis Pain: A Phase IIb/III Double ‐blind, Placebo‐controlled, Randomized Clinical Trial

ConclusionFasinumab provided improvements in OA pain and function, even in those benefitting little from previous analgesic. The observed “benefit to risk” relationship favors further clinical development to explore the lowest doses of fasinumab.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatology - June 16, 2019 Category: Rheumatology Authors: Paula Dakin, Stephen J. DiMartino, Haitao Gao, Jennifer Maloney, Alan J. Kivitz, Thomas J. Schnitzer, Neil Stahl, George D. Yancopoulos, Gregory P. Geba Tags: Full Length Source Type: research